A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
Heart attack survivors should be wary about taking a common group of painkillers known as non-steroidal anti-inflammatory drugs, say Danish researchers reporting in the journal Circulation this week, because the drugs could increase longer term risk of a second heart attack, or even death. Medical News Today